Investor Presentation

Date: June 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558 Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation Investors/Analysts Meeting, “The Growth Exchange 2026- Niveshak Samvad Roadshow”, to be held on Wednesday, June 24 ,2026 from 05:30 p.m.to 06:30 p.m. (IST). Request you to take the same on record. Thank you. Yours faithfully, For Fabtech Technologies Limited Hemant Mohan Anavkar Executive Director DIN: 00150776 Encl.: As mentioned above INVESTOR PRESENTATION · FY26 India’s Global Life Sciences Infrastructure Platform Engineering medicinal sovereignty across the pharma- emerging geographies. BSE Main Board · “FABTECH” 62+ countries 500+ projects delivered WHAT FABTECH DOES We build the factories that make Process medicines. Manufacturing & process equipment integrated into the production line. Every vaccine, IV solution and tablet is made inside a certified, sterile facility. Fabtech is the end-to-end turnkey provider that designs, engineers, builds and Cleanrooms & HVAC — the controlled validates those facilities — for pharma, biotech and environment medicines are made in. healthcare clients worldwide. Water What makes us rare: we manufacture the core Purified-water & utility systems engineered to systems in-house — Process, Air and Water — under pharmacopoeia grade. one roof, so quality, speed and cost stay in our control. THE GROUP ECOSYSTEM One integrated group platform. Three decades of engineering, presence across 62+ countries, and 78% of revenue from MENA, GCC & ECO Zone markets — an asset-light model that scales through in-house arms and strategic partners. 100% 100% 49% ~16% 33.33% MANUFACTURING CAPABILITIES Six capability domains, built in Fabtech group. Every solution is custom-designed and built at our own facilities — covering OSD, sterile liquids, vaccines, oncology, hormones & biosimilars. Cleanroom Sterilisation Containment Modular & bio-cleanrooms, HVAC Air & contained sterilisation, tunnels Isolation & containment for process, packaging and QC/QA. and internal infrastructure. and cleanroom equipment. Water & Utilities Process Custom-built Purified water, pure steam & WFI Powder processing, OSD & tablet Designed & manufactured in- generation and distribution. coating, lab to production scale. house for each client’s challenge. SERVICE OFFERING Turnkey engineering across the full value chain. Design Engineering Procurement Construction Management + Project Controls Advisory & Consulting Vendor Selection New Plant / Plant Technology Tie-up / Project Management Upgradation Transfer Design & Conception Equipment & Systems Audit, Training & Regulatory Compliance Post-Project Support Procurement Validation Experienced turnkey provider ensures Capex earmarked by pharmaceutical Increased capability through optimal → successful completion / upgrade of capex → companies capex utilisation projects From advisory to post-compliance support — start-to-end services covering the entire project value chain. T H E F Y 2 6 S T O R Y A resilient year, and a wider runway ahead. Operational continuity Growth visibility Regional expansion War Impact Project execution momentum held A ₹900+ Cr order book underpins UAE & Saudi localisation, JVs and a Near-term conflict disrupts delivery strong through freight volatility, revenue for the periods ahead, European acquisition extend reach schedules and lifts input costs but geopolitical disruption and elevated backed by a robust enquiry pipeline. into premium, high-margin markets. reshapes global supply chains in our input costs. favour — unlocking outsized long- term gains. F Y 2 6 R E S U L T S · Y E A R E N D E D 3 1 M A R C H 2 0 2 6 Scaling, with discipline. Standalone results ₹ in Crore | vs FY25 Revenue from Operations Operational Profit Reported Net Profit (PAT) Order Book ₹410.77 ₹36.60 ₹38.36 ₹900+ ↑ 25.7% YoY ↑ 17.0% YoY Normalised exceptionals Healthy visibility vs ₹326.67 in FY25 vs ₹31.27 in FY25 due to 16.66% vs ₹46.45 in FY25 Confirmed, ready to execute of TSA sale. STRATEGIC UPDATE Resilient delivery, an expanding platform. Strong order book position Resilient performance amid volatility Consolidated order book of ₹900+ Cr as of 31 March 2026 — providing Navigated logistics disruptions, freight challenges and input-cost pressures strong revenue visibility and growth momentum. with minimal impact — a robust execution model. Key strategic wins & expansion Positioning & outlook Entry into the Animal Health segment; KSA vaccine & advanced pharma Expanding across high-growth sectors & geographies into a scalable, projects; large-scale Africa pharma & infrastructure wins. diversified platform — positive outlook on a robust pipeline of complex, high- value projects. Consolidated order book · as of 31 Mar 2026 ₹900+ O R D E R B O O K & P I P E L I N E Visibility you can underwrite. Confirmed orders ready for execution. A confirmed book funds execution for the coming Conversion target periods, while a step-change in conversion turns a deep enquiry pipeline into structural growth. → Improving post European acquisition for structural visibility. STRATEGIC PROJECT WINS New mandates across high-growth markets. Marquee wins expanding our sector and geographic reach — anchoring the ₹900+ Cr order book. WEST AFRICA SAUDI ARABIA NORTH AFRICA Next-Gen Veterinary Facility Oral Solid Dosage Facility Animal Vaccine Project ₹49–52 Cr USD 7.05M USD 7.8M ~₹63.6 Cr ~₹65.5 Cr Project value SCOPE SCOPE SCOPE Supply, installation & commissioning of full Turnkey cleanroom, HVAC, MEP & utilities EU-GMP-compliant veterinary formulations facility. infrastructure. through to handover. TIMELINE TIMELINE TIMELINE Targeted for completion by Q1 FY27 23–27 months 11 months IMPACT IMPACT IMPACT Enables EU & African exports; long-term regional Expands West Africa footprint; supports local Entry into high-growth animal health; reference value. medicine manufacturing. strengthens KSA presence. BENCHMARK PROJECTS Firsts and largests that competitors can’t easily follow. Each landmark project builds regulatory credibility — creating reference moats, entry barriers and a repeat pipeline. LARGEST FIRST UAE’S ONLY FIRST FIRST IV Solution Facility Biosimilars Facility USFDA-Approved Oncology Project Flu Vaccine Project Facility Saudi Arabia Algeria Saudi Arabia Egypt United Arab Emirates GLOBAL PRESENCE Global engineering, local execution. India UAE Saudi Arabia Jordan countries delivered Engineering & Regional HQ & IV & oncology facilities MENA project delivery manufacturing base USFDA facility 500+ projects completed Egypt Algeria Nigeria 2000+ GCC · MENA · Africa Core growth corridor First biosimilars facility West Africa expansion specialised installations Flu vaccine project GROWTH STRATEGY · PLAN AHEAD Three levers to compound from here. European Acquisition Joint Ventures Working-Capital Strength Strengthening brand presence, entering Strengthening presence in KSA, East Africa Improved liquidity for smoother cycles — premium markets, expanding margins and enabling faster project acquisition and & North Africa with trusted local partners. diversifying the product portfolio. aggressive growth. MARKET OPPORTUNITY A large, structurally-funded addressable market. Fabtech’s scope covers 60%+ of project spend — Air, Water, Process, Cleanrooms and Utilities. Global TAM Fabtech SAM KSA Build-Out Africa $180B $28–30B $15B+ $60B+ Core geographies: GCC, Africa & Pharma manufacturing investment Medicine-production facilities, Turnkey pharma & biotech MENA. planned to 2030. WHO / Global Fund backed to projects, growing at ~8 [Showing first 8,000 characters — download PDF for full document]